News

Sort By

Study Links Actos to Development of Chronic Kidney Disease

Box of Actos

Researchers have discovered a link between the diabetes drug Actos and an increased risk of chronic kidney disease.

Doctors at Taiwan’s Kaohsiung Medical University found that diabetes patients who took Actos (pioglitazone) to help maintain blood glucose levels were almost four times more likely to develop chronic kidney disease than those who did not take the drug.

Chronic kidney disease (CKD), also known as chronic renal disease, involves the gradual loss of kidney functions. It is caused by conditions that damage kidneys. Complications include high blood pressure, anemia, nerve damage, weak bones and an increase in heart and blood vessel disease.

A 2014 report at the Centers for Disease Control (CDC) shows that more than 10 percent of adults in America — more than 20 million people — currently may have CKD.

Takeda Pharmaceutical Co., the maker of Actos, is facing more than 3,000 lawsuits that accuse it of not warning consumers that using the diabetes drug could increase their risk of bladder cancer. While the company added a label warning users of the risk of bladder cancer, it has not issued a warning about the risk of kidney disease.

Study Involved 35,000 People with Diabetes

Results of the study were published in January in PLOS One, a scientific journal by the Public Library of Science.

The study followed nearly 35,000 diabetes patients between 2005 and 2009. About 10 percent of the participants used Actos as part of their treatment for type 2 diabetes. Those who took Actos were mostly 60 years and older, female and had had type 2 diabetes for more than three years.

Researchers said that out of the 3,497 people in the study who took Actos, a total of 245 participants developed chronic kidney disease. The study’s researchers said that using Actos as the initial treatment “increased the risk of chronic kidney disease, and also for those with a history of hypertension and hyperlipidemia.”

The two major causes of chronic kidney disease are diabetes and high blood pressure, though other disorders can be involved. CKD typically occurs slowly, over a long period of time. However, if it’s not detected or goes untreated, it may lead to kidney failure and require dialysis or a kidney transplant.

Actos and Risk of Bladder Cancer

In 2011, the U.S. Food and Drug Administration ordered Takeda Pharmaceuticals to include a warning on the packaging of Actos to reflect the risk of bladder cancer. Germany and France ordered the drug pulled off the market in their countries.

Actos was designed to help the body properly use insulin, the hormone that helps deliver glucose to cells and regulates blood sugar levels. It was the top-selling diabetes medication in the world for several years. There are more than 25 million people with diabetes in the U.S., and that population increases by about 2 million people annually.

Sales of Actos in the U.S. topped out at $4.5 billion in 2011, but that number dropped to $1.52 billion in 2012, the year after news broke of its link to bladder cancer and when Takeda’s patent for the product expired.

Last modified: April 3, 2017

Author

Michelle Y. Llamas is a senior content writer. She is also the host the Drugwatch Podcast where she interviews medical experts as well as patients affected by drugs and medical devices. She has written medical and legal content for six years — including an article in The Journal of Palliative Medicine. Prior to writing for Drugwatch, she spent several years as a legal assistant for a personal injury law firm in Orlando. She obtained her Bachelor of Arts in English – Technical Communication from the University of Central Florida. She is a member of the American Medical Writers Association and the Florida Writers Association.

Hide Sources

  1. Lee, M., Hsiao, P., Yang, Y., Lin, K., Shin, S. (2014, January 10) The Association of Pioglitazone and urinary Tract Disease in Type 2 Diabetic Taiwanese: Bladder Cancer and Chronic Kidney Disease. Plosone.org. Retrieved from http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085479
  2. NA, (2014, January 10) 2014 National Chronic Kideny Disease Fact Sheet. Cdc.gov. Retrieved from http://www.cdc.gov/diabetes/pubs/factsheets/kidney.htm#1
  3. American Diabetes Association. (n.d.). Fast Facts Data and Statistics about Diabetes. Diabetes.org. Retrieved from http://professional.diabetes.org/admin/UserFiles/0%20-%20Sean/FastFacts%20March%202013.pdf
  4. Narva, A., Briggs, M., Jordan, R., Pavkov, M., Burrows, N., Williams, D. (2010, May) Toward a More Collaborative Federal Response to Chronic Kidney Disease. Ncbi.nlm.nih.gov. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875061/pdf/nihms199534.pdf
  5. Feeley, J. (2013, September 26) Takeda Failed to Properly Warn About Actos Risks, Jury Rules (1). Businessweek.com. Retrieved from http://www.businessweek.com/news/2013-09-26/takeda-failed-to-properly-warn-about-actos-risks-jury-rules-1